< Key Hightlight >

MARKET OUTLOOK

As per Triton’s research, the biosurgery market in Europe is expected to thrive at a compound annual growth rate of 5.88% during the period 2021-2028. Germany, Italy, Spain, France, Russia, the United Kingdom, and Rest of Europe shape the region’s market.

In the region, France is considered to have well-developed healthcare facilities, attracting several medical tourists in the country. As per the Fondation de France, obesity levels have become a major concern in the country, which is further expected to surge in the near future. This has resulted in a high number of surgeries, influencing the demand for biosurgery products. Furthermore, there is a high prevalence of cardiovascular diseases, resulting in high mortality rates. Hence, these factors increase the demand for biosurgery products, simultaneously boosting the biosurgery market on a positive path within France. 

On the other hand, rheumatoid arthritis has emerged as among the most common forms of autoimmune chronic inflammatory arthritis affecting a significant number of people across Italy. Moreover, this disease is more prevalent among older women; however, it can impact any age group. This increase in rheumatoid arthritis has enhanced the demand for biosurgery products across the nation’s cities. Therefore, as mentioned above, all these factors hold the ability to widen the scope and growth of the biosurgery market across Italy over the upcoming years. 

COMPETITIVE OUTLOOK 

The distinguished companies in the biosurgery market comprise B Braun Melsungen AG, RTI Surgical, Sanofi, Zimmer Biomet Holdings Inc, CSL Limited, and Stryker Corporation.